Drug Profile
CJ 40012
Alternative Names: CJ40012Latest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 28 Jan 2020 No recent reports of development identified for research development in Eye-disorders in South Korea
- 23 Dec 2015 Early research in Eye disorders (retinopathy) in South Korea (unspecified route) (CJ Healthcare pipeline, December 2015)